IL-15-based molecules and methods of use thereof

Patent metadata

Field	Value
Publication number	US-11679144-B2
Application number	US-202217825959-A
Country	US
Kind code	B2
Filing date	May 26, 2022
Priority date	Jun 30, 2014
Publication date	Jun 20, 2023
Grant date	Jun 20, 2023

Abstract

The invention features combination therapies using an IL-15-based superagonist complex and an antibody to effectively treat subjects with cancer and infectious diseases.

First claim

What is claimed is:

1. A pharmaceutical composition comprising
i) an effective amount of Bacillus Calmette-Guerin (BCG) and
ii) an effective amount of an Interleukin-15/Interleukin-15 Receptor alpha sushi (IL-15:IL-15RαSu) complex, wherein the IL-15 comprises a wild type IL 15.

2. The composition of claim 1 , wherein the IL-15:IL-15RαSu complex is comprised of IL-15 noncovalently bound to IL-15RαSu, wherein at least one binding partner of the IL-15:IL-15RαSu complex is a fusion protein, and wherein the at least one binding partner is covalently bound to a biologically active polypeptide.

3. The composition of claim 2 , wherein the IL-15RαSu is genetically fused to an immunoglobulin Fc domain, or functional fragment thereof, wherein an IL-15RαSuFc fusion protein is formed.

4. The composition of claim 3 wherein the IL-15/IL-15RαSuFc fusion protein comprises a dimeric complex comprising a dimeric IL-15RαSuFc and two IL-15 molecules.

5. The composition of claim 1 for use in the treatment of cancer.

6. The composition of claim 1 for use in the treatment of bladder cancer.

7. A kit for use in the treatment of cancer, the kit comprising:
(a) a first vial comprising an effective amount of Bacillus Calmette-Guerin (BCG), wherein the BCG is formulated for administration to a subject;
(b) a second vial comprising a wild-type Interleukin-15/Interleukin-15 Receptor alpha sushi (IL-15:IL-15RαSu) complex, wherein the wild type IL-15:IL-15RαSu complex is formulated for administration to a subject; and
(c) directions for use in the treatment of cancer.

8. The kit of claim 7 wherein the IL-15: 15RαSu complex comprises a dimeric IL-15RαSuFc fusion protein and two IL-15 molecules, thereby forming an IL-15:IL-15RαSuFc complex.

9. The kit of claim 7 , wherein the cancer is bladder cancer.

Assignees

• Altor Bioscience Llc

Inventors

• Liu Bai
• Rhode Peter
• Xu Wenxin
• Wong Hing C

Classifications

• C07K2319/30

  Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto · CPC title

• C07K14/5443

  IL-15 · CPC title

• A61K38/2086 Primary

  IL-13 to IL-16 · CPC title

• A61K39/04

  Mycobacterium, e.g. Mycobacterium tuberculosis · CPC title

• A61K39/39558

  against tumor tissues, cells, antigens · CPC title